CLIMARA Drug Patent Profile

Which patents cover Climara, and when can generic versions of Climara launch?

Climara is a drug marketed by Bayer Hlthcare and is included in two NDAs.

The generic ingredient in CLIMARA is estradiol; levonorgestrel. There are seventy-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estradiol; levonorgestrel profile page.

Summary for CLIMARA

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	94
Clinical Trials:	28
Patent Applications:	4,030
Drug Prices:	Drug price information for CLIMARA
Drug Sales Revenues:	Drug sales revenues for CLIMARA
What excipients (inactive ingredients) are in CLIMARA?	CLIMARA excipients list
DailyMed Link:	CLIMARA at DailyMed

See drug prices for CLIMARA

See drug sales revenues for CLIMARA

Recent Clinical Trials for CLIMARA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	Phase 2
Breast Cancer Research Foundation	Phase 2
Johns Hopkins University	Phase 4

See all CLIMARA clinical trials

Pharmacology for CLIMARA

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

Paragraph IV (Patent) Challenges for CLIMARA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CLIMARA	Transdermal System	estradiol	0.05 mg/day and 0.1 mg/day	020375		2005-09-12

US Patents and Regulatory Information for CLIMARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-004	Mar 5, 1999	AB2	RX	Yes	No
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003		RX	Yes	Yes
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-006	May 27, 2003	AB2	RX	Yes	No
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-005	May 27, 2003	AB2	RX	Yes	No

Expired US Patents for CLIMARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-004	Mar 5, 1999	5,223,261
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-002	Dec 22, 1994	5,223,261
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-005	May 27, 2003	5,223,261
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-003	Mar 23, 1998	5,223,261

International Patents for CLIMARA

See the table below for patents covering CLIMARA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	109357
Japan	H03502925
European Patent Office	0402407	SYSTEME D'ADMINISTRATION TRANSCUTANEE D'ESTRADIOL. (TRANSDERMAL ESTRADIOL DELIVERY SYSTEM.)
Australia	630347

Supplementary Protection Certificates for CLIMARA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0770388	2009/012	Ireland		PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
2782584	21C1058	France		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129

CLIMARA Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics of CLIMARA?

CLIMARA, a transdermal estrogen patch indicated for hormone replacement therapy (HRT) in menopausal women, faces a competitive landscape shaped by aging populations, alternative therapies, and regulatory standards.

Market Size and Segmentation

The global HRT market was valued at approximately $10 billion in 2022 and is projected to grow at a CAGR of 4% through 2030. CLIMARA's segment, transdermal estrogen therapies, accounts for roughly 35% of this market, driven by preferences for non-oral delivery systems and localized hormone absorption.

Key Competitors

• Alora (Estradiol patch): Market share ~25%
• Estraderm (Estradiol patch): Market share ~20%
• Patch formulations from generic firms: Increasing presence

Demographic Trends

• Women aged 45-60: Primary users
• Population growth in developed countries: Fuels demand
• Rising awareness of hormone therapy benefits and risks influences prescribing patterns

Regulatory and Healthcare Policies

• Reimbursement policies vary by country, affecting accessibility
• Increased scrutiny over safety profiles, especially concerning breast cancer and cardiovascular risks, influences prescription rates
• Approval of biosimilar estrogen patches could introduce price competition

Factors Influencing Market Dynamics

• Growing preference for transdermal over oral administration due to lower clotting risks
• The shift toward personalized medicine tailored to individual risk profiles
• Patent expiry of key formulations, potentially encouraging generic entry
• Emerging evidence on the benefits of hormone therapy prolongs its acceptance but also amplifies safety concerns

What Is the Financial Trajectory of CLIMARA?

Revenue Trends

• Estimated global annual sales of CLIMARA: ~$300 million (2022)
• Historical growth rate (2019-2022): Approximate CAGR of 5%
• North America accounts for 50% of sales; Europe 30%; other regions 20%

Market Penetration and Pricing

• Average wholesale price per patch (e.g., 25 mcg/24 hours): $150 for a 28-day supply
• Price sensitivity influences prescription volume, especially in markets with high generic competition
• Patent protection until 2024 limits generic penetration, allowing for premium pricing in select markets

Cost Structure

• Manufacturing costs: Estimated at 20-25% of sales, including raw materials and quality controls
• R&D expenses: Focused on formulation improvements and safety profile assessments, average of $15 million annually
• Marketing and distribution: Account for approximately 30% of expenditures

Profitability Outlook

• Operating margins estimated at 25-30%, contingent on market share and pricing strategies
• Patent expiration and increasing generic entries forecast potential margin compression post-2024
• Launch of new formulations or combination therapies could introduce growth avenues

Future Market and Financial Outlook

• The global transdermal estrogen market is projected to reach $4 billion by 2030
• CLIMARA’s market share may decline to 15-20% if generic competition intensifies
• Strategic diversification into related hormone therapies or combination patches could sustain revenue streams
• Potential for expansion in emerging markets where menopause management is gaining social acceptance

Key Takeaways

• The CLIMARA market is influenced by demographic trends, safety concerns, and regulatory changes
• Revenue growth is steady, but patent expiration poses a risk of price erosion
• Market share is vulnerable to generic competition, especially post-2024
• Cost management and product innovation remain critical for maintaining profitability
• Expansion into emerging markets and pipeline development are key for future growth

FAQs

Q1: How does CLIMARA compare to oral estrogen therapies?
Transdermal patches like CLIMARA generally have lower risks of blood clots and are preferred for women with certain cardiovascular risk factors.

Q2: What factors could accelerate CLIMARA’s market decline?
Introduction of biosimilar estrogen patches and new oral therapies with better safety profiles could reduce demand.

Q3: Are there regulatory risks for CLIMARA?
Yes; changes in safety guidelines, labeling, or approvals based on new evidence can impact sales and marketing strategies.

Q4: What opportunities exist for CLIMARA beyond menopause treatment?
Potential applications include hormone therapy for transgender populations or postmenopausal osteoporosis management, pending regulatory approvals.

Q5: How significant is the impact of patent expiry on CLIMARA’s revenue?
Patents expiring in 2024 could lead to a surge in generic competition, pressuring prices and reducing market share.

References

1. MarketWatch, "Hormone Replacement Therapy Market Size, Share & Trends," 2023.
2. Evaluate Pharma, "Global Market Data," 2022.
3. FDA, "Pregnancy and Lactation Labeling Rule," 2022.
4. IMS Health, "Pharmaceutical Pricing Trends," 2022.
5. WHO, "Menopause and Hormone Therapy," 2023.